Abstract 1678P
Background
Breast cancer have a significant impact on the life of married couples. Partners are faced with many challenges such as the heavy treatments and the body changes associated with the disease.
Methods
We conducted a study including patients treated for breast cancer in Salah Azaiz Institute. The aim was to evaluate the impact of cancer on the couple's relationship. The patients agreed to answer a marital adjustment questionnaire (MAQ).
Results
The study included 53 patients with a mean age of 52.25 years, ranging from 34 to 72 years. At the time of the study, 83% (n=44) had been married for between 3 and 60 years, with a mean of 22.5 years and a standard deviation of 11.4. The age at marriage was 27.80±6.9 years, with extremes ranging from 15 to 50 years. Fifteen per cent of patients had no children, and the number of children ranged from 1 to 5, with an average of 2.2. The average age difference between the married women and their partners was 5.3 years, with extremes ranging from one year to 23 years. More than half of the population studied in couple had intimacy problems (n=34),. The mean marital agreement score was 81.65 [41-120]. Eight couples no longer engaged in activities together outside the home and 39.5% (n=21) of them very little. Twenty-nine patients (54.7%) said that they almost never showed affection to their partners. The study of sexual activity showed an abstinence rate of 35.8% (n=19) compared to versus 0% before cancer. A quarter of our population had less than two sexual encounters per month after the disease, compared with 20.8% (n=11) and only 10% had more than 4 intercourses per month compared with 50.9% (n=27), before treatment. Twenty patients (37.3%) frequently disagreed about the sexual relationship. Fifty-four per cent (n=29) of the patients interviewed stated that they had a sexual complaint at the time of the survey: Among them, 32% (n=17) had spoken to their partners about the subject. Twenty-two (n=12) of the patients said they could no longer confide in their partner.
Conclusions
Breast cancer requires adjustments in married life, but with mutual support and open communication, couples can overcome these challenges together.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11